# A Study of Idelalisib and Rituximab in Elderly Patients With Untreated CLL or SLL

> **NCT01203930** · PHASE2 · TERMINATED · sponsor: **Gilead Sciences** · enrollment: 105 (actual)

## Conditions studied

- Chronic Lymphocytic Leukemia (CLL)
- Small Lymphocytic Lymphoma (SLL)

## Interventions

- **DRUG:** Idelalisib
- **DRUG:** Rituximab

## Key facts

- **NCT ID:** NCT01203930
- **Lead sponsor:** Gilead Sciences
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2010-10
- **Primary completion:** 2015-08
- **Final completion:** 2016-06
- **Target enrollment:** 105 (ACTUAL)
- **Last updated:** 2018-11-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01203930

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01203930, "A Study of Idelalisib and Rituximab in Elderly Patients With Untreated CLL or SLL". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01203930. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*